Regor Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Regor Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,751 sponsors by registered trial count).

5 total trials 2 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Regor Pharmaceuticals: 5 sponsored US clinical trials, 2 recruiting.

Regor Pharmaceuticals sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 1 trials.

Upper-quartile sponsor footprint

Regor Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,411 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Regor Pharmaceuticals pipeline

2 recruiting of 5 indexed (40% open); 1 completed (20%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.